Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
Nakamae H, Terada Y, Nakane T, Koh H, Nakamae M, Aimoto R, Hirose A, Hayashi Y, Nishimoto M, Inoue E, Yoshimura T, Inoue A, Koh KR, Yamane T, Hino M. Nakamae H, et al. Among authors: aimoto r. Gan To Kagaku Ryoho. 2010 Sep;37(9):1691-5. Gan To Kagaku Ryoho. 2010. PMID: 20841930 Japanese.
Serum cytokine profiles at the onset of severe, diffuse alveolar hemorrhage complicating allogeneic hematopoietic stem cell transplantation, treated successfully with pulse intravenous cyclophosphamide.
Koh H, Nakamae H, Koh KR, Ohsawa M, Nakane T, Takeoka Y, Aimoto R, Aimoto M, Wada-Inoue E, Terada Y, Yamane T, Hino M. Koh H, et al. Among authors: aimoto r. Acta Haematol. 2010;124(3):171-5. doi: 10.1159/000318013. Epub 2010 Oct 13. Acta Haematol. 2010. PMID: 20938173
Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.
Nakane T, Nakamae H, Koh H, Nakamae M, Hayashi Y, Nishimoto M, Yoshimura T, Inoue E, Inoue A, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Hino M. Nakane T, et al. Among authors: aimoto r. Int J Hematol. 2011 Apr;93(4):509-516. doi: 10.1007/s12185-011-0805-z. Epub 2011 Mar 12. Int J Hematol. 2011. PMID: 21394567
Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M. Koh H, et al. Among authors: aimoto r. J Exp Clin Cancer Res. 2011 Apr 10;30(1):36. doi: 10.1186/1756-9966-30-36. J Exp Clin Cancer Res. 2011. PMID: 21477348 Free PMC article.
Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma.
Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T, Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M. Terada Y, et al. Among authors: aimoto r. J Exp Clin Cancer Res. 2009 Aug 19;28(1):116. doi: 10.1186/1756-9966-28-116. J Exp Clin Cancer Res. 2009. PMID: 19689822 Free PMC article.